The latest quarterly results from telemedicine provider Hims & Hers Health have sent shockwaves through Wall Street, revealing a company caught between impressive expansion and worrying profitability trends. While the third-quarter revenue surged by an impressive 49%, reaching $598.9 million and surpassing analyst expectations, the celebration was tempered by disappointing earnings figures that have triggered a wave of concern among investors.
Profitability Concerns Overshadow Growth Metrics
Market experts are growing increasingly anxious as the company’s bottom line fails to keep pace with its top-line expansion. Hims & Hers reported earnings of just 6 cents per share, significantly below the 10 cents per share that analysts had projected. The situation appears even more concerning when examining operational efficiency—the company’s operating margin collapsed to a mere 1.9%, a dramatic decline from the 5.5% recorded during the same period last year.
This margin compression stems from aggressive spending in several key areas. The company has been pouring substantial resources into marketing initiatives, technological enhancements, and platform development in pursuit of market dominance. Meanwhile, the core online business demonstrated robust performance with a 50% increase, and the subscriber base expanded by 21% to reach 2.47 million customers.
Wall Street Responds with Downgraded Expectations
Financial institutions have responded to the mixed results with a series of rating adjustments and target price reductions. The average price target among analysts has been lowered from $47.42 to $46.67, with some firms taking more drastic measures. Seaport Research slashed its target from $66 to $59, while Citigroup issued a sell rating accompanied by a $30 price target, indicating significant concerns about the company’s valuation.
Bank of America analysts highlighted substantial challenges ahead, noting that regulatory changes within the telehealth industry and intensified competition in key therapeutic areas are putting pressure on the business model. Additional worries emerged from Morgan Stanley’s observation of declining app downloads, potentially signaling future difficulties in maintaining user growth.
Regulatory and Competitive Headwinds Intensify
The company encountered regulatory turbulence in September when the U.S. Food and Drug Administration issued a warning letter concerning marketing claims related to compounded semaglutid products. These products serve as alternatives to expensive pharmaceutical weight-loss injections, representing a significant growth area for the company.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Competitive pressures are mounting in the lucrative weight management sector, where large pharmaceutical companies are reducing prices for their GLP-1 medications. This pricing pressure creates additional complications for Hims & Hers, which has been aggressively expanding in this high-margin category.
A potential bright spot exists in the form of ongoing negotiations with Novo Nordisk to offer Wegovy injections through the Hims & Hers platform. However, CEO Andrew Dudum has cautioned investors against premature optimism, noting that no binding agreement has been reached and the outcome remains uncertain.
Ambitious Long-Term Strategy Meets Short-Term Reality
Despite the current challenges, management maintains ambitious growth targets. For the full 2025 fiscal year, the company projects revenue between $2.335 billion and $2.355 billion. Looking further ahead, leadership has set a staggering $6.5 billion revenue target for 2030, representing a quadrupling of business within just five years.
The company plans to achieve this expansion through several strategic initiatives: international market entry, expansion into new therapeutic areas including menopause management and testosterone deficiency, and enhanced personalization of their service offerings.
The fundamental question facing investors is whether Hims & Hers can transition from its current growth-at-all-costs approach to sustainable, profitable expansion. The recent quarterly performance illustrates a company heavily investing in future market position, but patience among shareholders appears to be wearing thin as profitability metrics continue to disappoint.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 8 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.
Hims & Hers: Buy or sell? Read more here...
